首页> 外文OA文献 >C1-01: Phase II open-label study to investigate PTK787/ZK 222584 (PTK/ZK) orally administered as a second-line monotherapy in patients with stage IIIB or stage IV non-small-cell lung cancer (NSCLC)

【2h】

C1-01: Phase II open-label study to investigate PTK787/ZK 222584 (PTK/ZK) orally administered as a second-line monotherapy in patients with stage IIIB or stage IV non-small-cell lung cancer (NSCLC)

机译：C1-01：II期开放标签研究，旨在研究IIB期或IV期非小细胞肺癌（NSCLC）患者口服PTK787 / ZK 222584（PTK / ZK）作为二线单药治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Gauler T.C.; Besse B; Meric J.B.; Gounant V; Fischer B; Overbeck T; Krissel H; Laurent D; Soria J.C.; Eberhardt W.E.E.;
展开▼
作者单位

展开▼
年度 2007
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase II trial of ptk787/zk 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage iiib/iv non-small-cell lung cancer (nsclc) [J] . GaulerT.C., BesseB., MauguenA., Annals of oncology: official journal of the European Society for Medical Oncology . 2012,第3期

机译：ptk787 / zk 222584（vatalanib）的II期临床试验，对于复发或进展期iiib / iv期非小细胞肺癌（nsclc）的患者，每天口服或分两次每日剂量作为二线单药治疗
2. Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-linen monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) [J] . W. E. E. Eberhardt Annals of Oncology . 2012,第3期

机译：PTK787 / ZK 222584（vatalanib）的II期临床试验，对于复发或进展期IIIB / IV期非小细胞肺癌（NSCLC）的患者，每天口服或分两次每日剂量作为二麻单药治疗
3. 949 POSTER Antiangiogenesis as new treatment modality in ovarian cancer: a phase Ib, open label, safety and pharmacokinetics (PK) study of escalating doses of PTK787/ZK222584 (PTK/ZK) in combination with paclitaxel and carboplatin in patients (pts) with stage IC to IV epithelial ovarian cancer [J] . European Journal of Cancer Supplements . 2005,第2期

机译：949 POSTER抗血管生成作为卵巢癌的新治疗方法：Ib期，开放标签，安全性和药代动力学（PK）研究，逐步增加PTK787 / ZK222584（PTK / ZK）剂量与紫杉醇和卡铂联合治疗在分期患者中的作用IC至IV上皮性卵巢癌
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. Evaluation of Symptom Management in Patients with Advanced Stage (IIIB and IV) Non-Small Cell Lung Cancer [D] . Mann, LaTonya E. 2018

机译：晚期（IIIB和IV）非小细胞肺癌患者症状管理的评估
6. Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre open-label phase I–II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer [O] . Floriana Morgillo, Morena Fasano, Carminia Maria Della Corte, 2017

机译：METAL（晚期肺癌中的METformin）研究的安全运行结果：一项多中心开放标签的I-II期二甲双胍联合厄洛替尼用于IV期非小细胞期患者二线治疗的研究肺癌
7. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as a biomarker for the effect of PTK787/ZK 222584 as second-line mono-therapy in patients with stage IIIB or stage IV non-small-cell lung cancer (NSCLC). [O] . Horsfield, Mark A., Morgan, Bruno, Krissel, H., 2006

机译：动态对比增强磁共振成像（DCE-MRI）作为PTK787 / ZK 222584作为IIIB期或IV期非小细胞肺癌（NSCLC）患者二线单一疗法疗效的生物标志物。
8. Phase II Study of a HER-2/neu (HER2) Intracellular Domain (ICD) Peptide- Based Vaccine Administered to Stage IIIB and IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab Monotherapy; Annual rept. 27 Apr 2007-26 Apr 2008 [R] . Disis, M. L. 2008

机译：对接受曲妥珠单抗单一疗法的IIIB和IV期HER2阳性乳腺癌患者施用HER-2 / neu（HER2）细胞内结构域（ICD）基于肽的疫苗的II期研究;年度报告。 2007年4月27日至2008年4月26日

C1-01: Phase II open-label study to investigate PTK787/ZK 222584 (PTK/ZK) orally administered as a second-line monotherapy in patients with stage IIIB or stage IV non-small-cell lung cancer (NSCLC)

著录项

引文网络

相似文献

相关主题

期刊订阅